From the smallest biotech to the biggest pharmaceutical stock The Motley Fool's Market Check-Up covers the health-care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.
In this segment, health-care analyst David Williamson looks into GlaxoSmithKline (GSK 0.06%) and the recent allegations of widespread corruption plaguing the company in China. David looks at an article from Reuters reporting that some of the company's executives may be charged, but it's unlikely that the company itself will be. David also examines how badly sales have suffered under the shadow of these allegations, and how much of an impact Chinese sales have on the bigger picture for GlaxoSmithKline.
